NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Monday

NRx Pharmaceuticals (NASDAQ:NRXP) will likely be posting its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect NRx Pharmaceuticals to announce earnings of ($0.09) per share and revenue of $1.33 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. On average, analysts expect NRx Pharmaceuticals to post $-0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP opened at $3.58 on Monday. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $2.92. The firm has a market capitalization of $129.70 million, a PE ratio of -3.28 and a beta of 2.18.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on NRXP shares. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. BTIG Research lowered their price objective on shares of NRx Pharmaceuticals to $10.00 and set a “buy” rating on the stock in a research report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, April 27th. Finally, Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its stake in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares during the last quarter. Vanguard Group Inc. boosted its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth $994,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.